{"a":[{"_":"Ipsen’s Botox rival Dysport charts new horizons with dual phase 3 wins in migraine","$":{"href":"/pharma/ipsen-botox-rival-dysport-charts-new-territory-dual-phase-3-wins-migraine","hreflang":"en"}}]}
Phase 3positiveDysportPositive
AI Analysis
Summary
Ipsen announced that Dysport successfully met primary endpoints in two phase 3 trials for both episodic and chronic migraine prevention, marking a first for the neurotoxin market in this indication.
Clinical Trial Data
Phase
3
Primary Endpoint
Met
Outcome Details
Two phase 3 trials met primary goals for prevention of episodic and chronic migraines
Importance:8/10
Sentiment:
0.85
neurotoxinmigrainephase 3DysportIpsen
Related Companies
Read the original article
Published by FiercePharma on July 9, 2026 9:50 AM